百诚医药：2025年第二次临时股东大会决议公告

Group 1 - The core point of the article is that Baicheng Pharmaceutical announced the approval of a proposal to permanently supplement working capital with part of the raised funds during its second extraordinary general meeting of shareholders in 2025 [2] Group 2 - The announcement was made on the evening of August 20, indicating the company's proactive approach to managing its financial resources [2] - The decision reflects the company's strategy to enhance liquidity and operational flexibility by utilizing excess raised funds [2]